Detection of P53, Estrogen Receptors and Progesterone Receptors in Breast Cancer

Abstract

This study aimed to detect P53 estrogen receptors (ER) and progesterone receptors (PR) in breast cancer patients using immunohistochemical method Fifty paraffin embedded tissue blocks previously diagnosed as breast cancer were randomly selected, sectioned and stained immunohistochemically for the detection of P53 mutation, estrogen receptors and progesterone receptors The obtained data were analyzed using SPSS computer program The patients information was collected from the archived files of patients Histopathology diagnosis of study subjects revealed invasive ductal carcinoma in 41 (82%) samples invasive mammary carcinoma in 2 (4%) samples mucinous carcinoma in 3 (6%) samples papillary carcinoma in 2 (4%) samples tubulo lobular carcinoma in 1(2%) samples, and malignant stromal tumor in 1 (2%) sample. The majority were in grade 3, 25 (50%) patients while those with grade 2 were 14 (24%) patients and grade 1 only one patient (2%), and the not graded were 10 (20%) patients. Positive expression of p53 among study subjects represented 30 (60.0%) patients and the remaining 20 (40.0%) were negative with no association between p53 mutation and histopathological diagnosis (P.value>0.05). ER status showed positive expression in 24 (48.0%) patients and negative in 26 (52.0%), PR showed positive expression in 18 (36.0%) patients and negative in 32 (64.0%) patients. ER and PR showed insignificant association histopathological diagnosis (P.value>0.05). The study concludes that the mutated P53 is expressed in most breast cancer tissues with no association between p53 and histopathology diagnosis, also no association with ER and PR receptors